| 1 |
Integrated genomic analyses of ovarian carcinoma
Debra Bell et al. · Nature
Open access255 authors |
28 Jun 2011 |
8,268 |
| 2 |
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin et al. · New England Journal of Medicine
Open access |
31 May 2015 |
8,266 |
| 3 |
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al. · New England Journal of Medicine
Open access |
5 Jun 2011 |
7,801 |
| 4 |
Comprehensive molecular characterization of gastric adenocarcinoma
Adam Joel Bass et al. · Nature
Open access258 authors |
23 Jul 2014 |
6,680 |
| 5 |
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Robert D. Schreiber, Lloyd J. Old, Mark John Smyth · Science
|
24 Mar 2011 |
6,561 |
| 6 |
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al. · New England Journal of Medicine
Open access |
11 Sep 2017 |
5,453 |
| 7 |
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice Lee Kwak et al. · New England Journal of Medicine
Open access |
27 Oct 2010 |
4,517 |
| 8 |
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine
Open access |
20 Oct 2018 |
4,469 |
| 9 |
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al. · New England Journal of Medicine
Open access |
Dec 2018 |
4,157 |
| 10 |
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al. · Nature
Open access1,384 authors |
5 Feb 2020 |
3,854 |
| 11 |
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin et al. · New England Journal of Medicine
Open access |
28 Sep 2019 |
3,784 |
| 12 |
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Christos Stelios Karapetis, Shirin Khambata‐Ford, Derek J. Jonker et al. · New England Journal of Medicine
|
22 Oct 2008 |
3,629 |
| 13 |
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty, Igor J. Puzanov, Kevin B. Kim et al. · New England Journal of Medicine
Open access |
25 Aug 2010 |
3,581 |
| 14 |
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sánchez-Vega et al. · Cell
Open access779 authors |
Apr 2018 |
3,452 |
| 15 |
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Alice Tsang Shaw et al. · New England Journal of Medicine
Open access |
Jun 2013 |
3,429 |
| 16 |
Pan-cancer analysis of whole genomes
Lauri A. Aaltonen et al. · Nature
Open access1,324 authors |
5 Feb 2020 |
3,360 |
| 17 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Ann Burtness et al. · The Lancet
Open access219 authors |
Nov 2019 |
3,344 |
| 18 |
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Döhner et al. · Blood
Open access |
7 Jul 2022 |
3,286 |
| 19 |
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Benjamin J. Solomon, Tony S.K. Mok, Dong‐Wan Kim et al. · New England Journal of Medicine
Open access |
3 Dec 2014 |
3,251 |
| 20 |
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Roberto Salgado et al. · Annals of Oncology
Open access |
11 Sep 2014 |
3,221 |
| 21 |
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew James Souers et al. · Nature Medicine
|
6 Jan 2013 |
3,089 |
| 22 |
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
J. Peter Donnelly et al. · Clinical Infectious Diseases
Open access |
8 Oct 2019 |
2,973 |
| 23 |
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline B. Kuchenbaecker et al. · JAMA
Open access |
20 Jun 2017 |
2,963 |
| 24 |
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden, Melissa J. Peart, Ricky W. Johnstone · Nature Reviews Drug Discovery
Review |
Sep 2006 |
2,936 |
| 25 |
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al. · Blood
Open access |
29 Jun 2022 |
2,906 |
| 26 |
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael James Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology
Open access |
19 Jul 2017 |
2,883 |
| 27 |
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Joshua David Cohen et al. · Science
Open access |
18 Jan 2018 |
2,879 |
| 28 |
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Daniel J. Klionsky et al. · Autophagy
Open access2,930 authors |
2 Jan 2021 |
2,743 |
| 29 |
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology
Open access |
22 Feb 2009 |
2,681 |
| 30 |
Lung cancer
Alesha A. Thai, Benjamin J. Solomon, Lecia Van Dam Sequist et al. · The Lancet
|
21 Jul 2021 |
2,661 |
| 31 |
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett et al. · The Lancet
|
Oct 2006 |
2,626 |
| 32 |
Comprehensive genomic profiles of small cell lung cancer
Julie George et al. · Nature
Open access |
10 Jul 2015 |
2,448 |
| 33 |
International network of cancer genome projects
Jennifer L. Jennings et al. · Nature
Open access256 authors |
13 Apr 2010 |
2,439 |
| 34 |
Genome-wide association study identifies novel breast cancer susceptibility loci
Douglas F. Easton et al. · Nature
Open access239 authors |
27 May 2007 |
2,342 |
| 35 |
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude R. Canon et al. · Nature
|
30 Oct 2019 |
2,329 |
| 36 |
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann Sebastian De Bono, Joaquı́n Mateo, Karim S. Fizazi et al. · New England Journal of Medicine
Open access |
28 Apr 2020 |
2,322 |
| 37 |
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah‐Jane Dawson, Dana W.Y. Tsui, Muhammed Murtaza et al. · New England Journal of Medicine
Open access |
13 Mar 2013 |
2,250 |
| 38 |
Apoptosis
Ricky W. Johnstone, Astrid A. Ruefli, Scott W. Lowe · Cell
Open access |
2002 |
2,248 |
| 39 |
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al. · The Lancet
Open access |
2 Oct 2013 |
2,223 |
| 40 |
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian, Hubing Shi, Qi Wang et al. · Nature
Open access |
24 Nov 2010 |
2,203 |
| 41 |
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey Alan Sosman et al. · New England Journal of Medicine
Open access |
22 Feb 2012 |
2,170 |
| 42 |
Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS ® ) Society Recommendations: 2018
Ulf O Gustafsson et al. · World Journal of Surgery
Open access |
13 Nov 2018 |
2,140 |
| 43 |
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely, Michael H. Kershaw, Robert D. Schreiber et al. · Annual Review of Immunology
Review |
Mar 2011 |
2,113 |
| 44 |
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso et al. · Annals of Oncology
Open access |
11 Oct 2016 |
2,075 |
| 45 |
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al. · The Lancet
|
22 Mar 2020 |
2,053 |
| 46 |
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice Tsang Shaw et al. · New England Journal of Medicine
Open access |
27 Sep 2014 |
2,013 |
| 47 |
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew Warwick Roberts, Matthew Steven Davids, John M. Pagel et al. · New England Journal of Medicine
Open access |
6 Dec 2015 |
1,929 |
| 48 |
The Hippo pathway and human cancer
Kieran F. Harvey, Xiaomeng Zhang, David Morgan Thomas · Nature reviews. Cancer
Review |
7 Mar 2013 |
1,926 |
| 49 |
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont et al. · New England Journal of Medicine
Open access |
15 Apr 2018 |
1,906 |
| 50 |
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice Tsang Shaw, Beow Yong Yeap, Mari A. Mino-Kenudson et al. · Journal of Clinical Oncology
Open access |
10 Aug 2009 |
1,896 |